We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fat…

In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on callUlrich Neumann, Sr. Director, US Access ulrich.neumann@certara.comAdditional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed …

Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients. Experts on callShontelle Dodson, SVP, AstellasMatt Portch, VP Sunovion,Gergana Zlateva, VP Pfizer,Terrill Jordan, CEO of the RCCA provider networkUlrich Neumann, Sr. Director, Head US Access, Certar…

In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting? Experts Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, CertaraLee Stern, VP, Business Deve…